Novavax, Inc.NASDAQ: NVAX

Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India

· Issued by Novavax, Inc.

On 6ix: 6ix.com/news/novavax-and-serum-institute-of-india-announce-first-emergency-use-authorization-of

Watch Novavax's latest callNovavax (NASDAQ:NVAX) Q2 2026 Earnings Call · Replay · Aug 6Read the transcript of Novavax (NASDAQ:NVAX) Q2 2026 Earnings Call
  • First authorization of Novavax' COVID-19 vaccine in adolescent population received
  • Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized for adolescents ≥12 to

Novavax, Inc. on 6ix

Story so far

Earlier from Novavax

Later from Novavax

All Novavax news releases